Log In
BCIQ
Print this Print this
 

biosimilar rituximab (CT-P10)

  Manage Alerts
Collapse Summary General Information
Company Celltrion Inc.
DescriptionBiosimilar of rituximab, a CD20 inhibitor
Molecular Target CD20
Mechanism of ActionAntibody; Biosimilar
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$160.0M

$160.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

10/06/2016

$160.0M

$160.0M

0

10/19/2009

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today